The DNA-packaging pRNA of bacterial virus phi29, which forms dimers and then hexamers, contains two independent tightly self-folded domains. Circularly permuted pRNAs were constructed without impacting pRNA folding. Connecting the pRNA 5 0 /3 0 ends with variable sequences did not disturb its folding and function. These unique features, which help prevent two common problems -exonuclease degradation and misfolding in the cell, make pRNA an ideal vector to carry therapeutic RNAs. A pRNA-based vector was designed to carry hammerhead ribozymes that cleave the hepatitis B virus (HBV) polyA signal. The chimeric HBV-targeting ribozyme was connected to the pRNA 5 0 /3 0 ends as circularly permuted pRNA. Two cis-cleaving ribozymes were used to flank and process the chimeric ribozyme. The hammerhead ribozyme including its two arms for HBV targeting was able to fold correctly while escorted by the pRNA. The chimeric ribozyme cleaved the polyA signal of HBV mRNA in vitro almost completely. Cell culture studies showed that the chimeric ribozyme was able to enhance the inhibition of HBV replication when compared with the ribozyme not escorted by pRNA, as demonstrated by Northern blot and e-antigen assays. pRNA could also carry another hammerhead ribozyme to cleave other RNA substrate. These findings suggest that pRNA can be used as a vector for imparting stability to ribozymes, antisense, and other therapeutic RNA molecules in vivo.
Introduction
The use of ribozymes [1] [2] [3] [4] [5] [6] [7] [8] for the treatment and prevention of diseases has the potential to revolutionize biotechnology. [9] [10] [11] [12] Hammerhead ribozymes, for instance, have been used to cleave RNA in transgenic plants and animals. [13] [14] [15] [16] [17] [18] Although it is clear that hammerhead ribozymes can cleave specific viral RNA or mRNA in cell-free systems effectively, the efficiency of cleavage in vivo remains to be improved. 19 Part of the explanation for the low efficiency of ribozymes in an intracellular environment is the misfolding and the degradation of ribozymes by exonucleases present in cells. 9 One method that has been used to protect the ribozymes from intracellular degradation is to connect them to a vector RNA such as tRNA. 20 Nevertheless, new approaches in using RNA as a vector to escort and chaperone ribozymes in vivo should be further investigated in order to improve this technique, which has shown great potential for improving human health and agricultural productivity.
A viral-encoded 120-base RNA has been shown to play a novel and essential role in packaging bacterial virus phi29 DNA into procapsids. 21 This RNA is termed packaging RNA or 'pRNA'. Computer models of the three-dimensional (3D) structure of a pRNA monomer, dimer and hexamer has been constructed 22 based on experimental data derived from photoaffinity crosslinking, 23, 24 chemical modification and chemical modification interference, [25] [26] [27] complementary modification, [28] [29] [30] [31] [32] nuclease probing, 24, 33 oligo targeting, 34 competition assays, 35, 36 and cryo-atomic force microscopy. 25, 27, 37 pRNA hexamer docking with the connector crystal structure reveals a very impressive match with available biochemical, genetic, and physical data concerning the 3D structure of pRNA. 22 Studies on the structure and function of pRNA have revealed that pRNA self-folds tightly [24] [25] [26] ( Figure 1 ). Extensive investigation has demonstrated that the pRNA monomer contains two functional domains (Figure 1 ): the procapsid binding domain and the DNA packaging domain. The procapsid binding domain is located at the central part of the pRNA molecule, 23 ,33,37 bases 23-97, while the DNA packaging domain is located at the 5 0 /3 0 paired ends. The 5 0 and 3 0 ends have been found to be proximate, and several kinds of circularly permuted pRNA have been constructed. 30, 38 All of these findings suggest that pRNA could be a vector to escort and chaperone small therapeutic RNA molecules. A chimeric hammerhead ribozyme targeting the polyA signal of the mRNA of hepatitis B virus (HBV), the causative agent of a serious worldwide disease, was constructed to test this possibility. of the molecule. 23, 33, 37 The other is the DNA-packaging domain composed of the 5 0 -3 0 paired ends 23, 29, 33 (for review see Guo 39 ). These two domains are compact and fold independently, which hint that exogenous RNA might be connected to the end of the pRNA without affecting pRNA folding.
At least 120 nonspecific bases were extended from the 3 0 end of pRNA or aptRNA 55 without hindering the folding and function of the pRNA To investigate whether additional burdens can be imposed on the pRNA, the 3 0 ends of the pRNA were extended with variable lengths. It was found that at least 120 bases could be added to the 3 0 end of the pRNA without significant interference of pRNA function (Table  1) . Such additions included end labeling of pRNA with biotin, pCp, DIG, and phosphate (data not shown). These results indicated that the 117-base pRNA folded independent of bases extended from its 3 0 -end.
Construction of biologically active circularly permuted pRNAs revealed that interruption of pRNA internal bases did not affect the global folding of the pRNA
The feasibility of constructing circularly permuted RNAs lies in the close proximity of the native phi29 pRNA 5 0 and 3 0 ends 29 ( Figure 2 ).
To construct circularly permuted -pRNA (cp-pRNA), two tandem pRNA-coding sequences separated by a 3-or 18-base loop sequence were cloned into a plasmid ( Figure 2 ). PCR primer pairs, such as P6/P5, complementary to various locations within pRNA coding sequences, can be designed to synthesize PCR fragments for the transcription of cp-pRNAs. It was found that neither the 3-base nor a 18-base loop interferes with the biological activity of the pRNA molecule. Therefore, most of the internal bases could be used as new termini for constructing active cp-pRNA. 30, 38 Since linking the 3 0 and 5 0 ends of the pRNA with nucleotide sequences of variable lengths did not affect the pRNA activity, this is an indication that pRNA and the linking sequence fold independently. These findings implying that a ribozyme could be placed between the 3 0 and 5 0 ends of the pRNA could be able to fold without being influenced by the sequence and folding of pRNA.
Construction of a chimeric pRNA/ribozyme targeting the hepatitis B virus polyA signal for in vitro studies
The hammerhead ribozyme was designed to cleave a 137-nucleotide HBV-polyA fragment substrate into two fragments of 70 and 67 nucleotides. 40 . The HBV-targeting ribozyme was connected to the 5 0 and 3 0 ends of pRNA, phi29 pRNA as ribozyme escort to destroy hepatitis B virus S Hoeprich et al and the pRNA was reorganized into a circularly permuted form. Two cis-cleaving ribozymes were added to flank the pRNA and HBV-targeting ribozyme. The entire cassette of the in vitro plasmid was under the control of a T 7 promoter. During transcription of the cassette, the transcript self-cleaved to produce a chimeric ribozyme (pRNA-RzA) containing the HBVtargeting ribozyme that was connected to the pRNA ( Figure 3 ).
The HBV-polyA fragment was cleaved completely by a hammerhead ribozyme harbored in a pRNA vector A dsDNA fragment encoding the pRNA chimera, pRNA-RzA (Table 2) , was made by PCR. The pRNARzA ribozyme and the HBV-polyA substrate RNA were generated by in vitro transcription with T 7 polymerase, using linear DNA as a template for run-off transcripts. This pRNA-RzA ribozyme transcription product then underwent two cis-cleavage reactions to free itself from extraneous RNA flanking sequences. These two ciscleavages were achieved by two ribozymes that flanked the chimera sequence. One cis-ribozyme (63 nt) was 5 0 to the chimera, while the other cis-ribozyme (46 nt) was 3 0 to the chimera ( Figure 3 ). The cis-cleavage reactions predominantly occurred during the time the pRNA-RzA ribozyme was transcribed ( Figure 3 ). The processed product of the cis-cleaved transcript, a 188 mer, was a major band in the gel and was purified. Examination of the gels used to purify pRNA-RzA ribozyme under UV light produced three distinct shadows. The slowly migrating band was the pRNA-RzA ribozyme. The other two bands that migrated much more quickly were the 5 0 -and 3 0 -cis-cleaving ribozymes. This indicates that the ciscleavage is complete (data not shown). Cleavage of HBVpolyA substrate by the functional chimera pRNA-RzA ribozyme is shown in Figure 4 . The lane labeled pRNARzA shows a control reaction that did not contain HBVpolyA, and the lane labeled HBV-polyA shows a control reaction that did not contain pRNA-RzA ribozyme. The predicted 67 base and 70 base cleavage products are seen as one band for the cleavage reaction that included both HBV-polyA and pRNA-RzA ribozyme. The ribozyme pRNA-RzA, which contains a pRNA moiety, was able to cleave the substrate HBV-polyA with nearly 100% efficiency.
Testing of chimeric pRNA/ribozymes with hammerhead ribozyme targeting another substrate
Another model, a U7snRNA system, 9 was used to determine whether the pRNA could harbor other hammerhead ribozymes to function in substrate cleavage. The RNAs used in these experiments were generated by T 7 polymerase transcribed in vitro either by using PCR-generated templates or by cloning sequences into a plasmid, linearing the plasmid, and making run-off transcripts.
The relative abilities of the U7-targeting ribozyme (47 bases), RzU7, and the U7-targeting pRNA-ribozyme (168 bases), RzU7-pRNA, to cleave an U7snRNA fragment were compared. The ribozyme cleavage reaction was done as a control experiment to demonstrate that ribozyme reactions work correctly without any modifications. The results reveal that the RzU7-pRNA ribozyme was able to cleave the substrate with results comparable to the control RzU7 ribozyme ( Figure 4 ). Extended investigation revealed that specific hammerhead ribozymes harbored by pRNA, constructed with an approach similar to that for HBV, were able to cleave other respective substrates (data not shown).
Enhancement of inhibition of HBV replication in the cell by pRNA vector revealed in the e-antigen (e-Ag) assay
The e-antigen (e-Ag) assay was performed to investigate whether the pRNA could enhance the inhibition of HBV replication by hammerhead ribozyme. The e-Ag is expressed by translation from a start site upstream of the precore (pre-c) coding region, having a nearly identical amino-acid sequence as the core antigen, while Assay of e-Ag revealed that pRNA enhanced the inhibition effect of ribozyme by comparing the e-Ag level of cells transfected with plasmids pcRzA (expressing hammerhead ribozyme only), pRNA-RzA (expressing the chimeric ribozyme with pRNA vector), pCdRzA (expressing the disabled ribozyme), and vector only ( Table 3 ). The slight inhibition by the catalytically inactive ribozyme may be due to an antisense mechanism that involves the hybridization of arms I and II to the complementary HBV sequences.
Enhancement of inhibition of HBV replication in the cell by pRNA vector as revealed by Northern blot
The plasmid pRNA-CRzA was constructed and carried a hammerhead ribozyme that targeted the HBV-polyA signal. The design of the pRNA-CRzA plasmid used for cell culture studies was basically the same as the one used for in vitro, except that the CMV promoter was used instead of the T 7 promoter that was used for the in vitro studies (Table 2) . Two versions of this ribozyme were tested: pRNA-RzA ribozyme, which contained a pRNA moiety, and RzA ribozyme, which did not ( Figure 5 ). Both plasmids contain sequences coding for a hammerhead ribozyme targeting the HBV-polyA signal including 
Discussion
Antigen assays and Northern blot have demonstrated that pRNA can chaperone and escort the hammerhead ribozyme to function in the cell, enhancing the cleavage efficiency and inhibition effect of the ribozyme on HBV.
The mechanism for such increase in ribozyme activity is because of the fact that the pRNA can prevent the ribozyme from misfolding and protect the ribozyme from degradation by exonucleases present in cells. The pRNA molecule contains two independently functional domains: the procapsid binding domain and the DNApackaging domain. It was demonstrated that exogenous RNA can be connected to the end of the pRNA without affecting pRNA folding. At least 120 nonspecific bases were extended from the 3 0 end of pRNA without hindering the folding or function of the pRNA, indicating that the 117-base pRNA was folded independent of No uncleaved substrate was seen. In order to use equal molar concentrations of RzA and pRNA-RzA in cleavage reaction, a large mass of pRNA-RzA was used. The other materials shown between the chimeric ribozyme and the cleaved products are degraded chimera ribozyme because of the high RNA concentration in this gel and the large size of the chimeric ribozyme. Even a small percent of degradation resulted in visible degradation products. Owing to the secondary structure and incomplete denaturation by urea, the migration rate of RNAs did not match perfectly with the size. phi29 pRNA as ribozyme escort to destroy hepatitis B virus S Hoeprich et al bases extended from its 3 0 -end. In addition, construction of biologically active circularly permuted pRNAs revealed that interruption of pRNA internal bases did not affect the global folding of the pRNA. The demonstration that the linking of the 3 0 and 5 0 ends of pRNA with variable lengths of nucleotide sequence, which did not affect the pRNA activity, is an indication that pRNA and the linking sequence fold independently. These findings suggest that a ribozyme could be placed between the 3 0 and 5 0 ends of the pRNA and will be able to fold without being influenced by the original pRNA sequence.
Phi29 pRNA has a strong drive to form dimers ( Figure  6 ), 22, 25, 27, 42 and dimers are the building blocks of hexamers. 37, [43] [44] [45] The formation of hexamers or dimers can be controlled by manipulating the sequences of the two interacting loops.
22,25,27,42, 44 The formation of pRNA dimers ( Figure 6 ) might also assist in stabilizing pRNA/ ribozyme chimera molecules. As long as the openings of the circularly permutated pRNAs are close to an area of dimer formation, the tertiary structure can help prevent exonucleases from accessing the ends of the RNA molecules. Formation of dimer or hexamer also facilitates the ability to carry multiple therapeutic agents. For example, one of the pRNA subunits of a hexamer could carry the hammerhead ribozyme, and the other pRNA subunit could carry a SiRNA, a hairpin ribozyme or an antisense RNA (Figure 7) . Applications of multiple therapeutic agents might enhance the efficiency of the in vivo therapy.
The multivalent subunit of pRNA might facilitate the specific targeting and delivery of the ribozyme. For example, one of the subunits can be used to carry an RNA molecule that interacts with a cell-surface receptor. Binding of the dimer or hexamer pRNA to the specific receptor would enable the specific delivery of the RNA complex to the cell via endocytosis. The specific receptorbinding RNA molecules can be isolated through systematic evolution of ligands by exponential enrichment (SELEX). 46, 47 Starting with a library containing random RNA sequences, in vitro evolution techniques allow for the selection of the RNA molecules that are able to bind a specific ligand or receptor. [48] [49] [50] [51] The receptorbinding RNA will be inserted into the pRNA vector by the same method described in this report. The chimeric RNA carrying the therapeutic RNA molecules and the chimeric RNA carrying the antireceptor could be mixed to form dimers or hexamers via inter-RNA loop/loop interaction as reported previously 37, [43] [44] [45] (Fig. 7) . Phylogenetic analysis of pRNAs from Bacillus subtilis phages SF5, B103, phi29, PZA, M2, NF, and GA1, 42, 52, 53 shows very low sequence identity and few conserved bases, yet the family of pRNAs appears to have similar predicted secondary structures 42, 52 ( Figure 8 ). All seven pRNAs of these phages contain both the right-and lefthand loops, which form a loop/loop interaction via W.C. base pairing. Complementary sequences within the two loops are found in each of these pRNAs. Therefore, these pRNAs, including aptRNA, 55 could also be used as vector to carry small therapeutic RNA molecules (Figure 8) .
The results from these ribozyme-mediated suppression experiments could be applied to other cell types, including those of many plant and animal species. Transgenic plants and animals could then be developed for a variety of purposes, if the chimeric ribozyme-pRNA The CMV vector, pCRzA, pRNA-RzA, and disabled ribozyme plasmid pCdRzA were transfected into HepG2 cells together with the HBV expressing plasmid p3.6II and the b-galactosidase expressing plasmid pcDNA4LacZ serving as an internal control. The e-Ag in the culture medium and cell lysates were measured by a commercial ELISA kit (Sino-American Co.) and normalized against b-galactosidase activity. The amount of e-Ag expressed by CMV vector was arbitrarily taken as 1.0. 
Materials and methods
Construction of plasmids pRNA-RzA and pRNA-CRzA
The in vitro plasmid pRNA-RzA encoding the chimera ribozyme was constructed by using restriction enzymes XbaI and KpnI to remove the sequence encoding the unmodified ribozyme from the plasmid pRzA, which encoded the ribozyme targeting the HBV polyA signal. 41 Then, a dsDNA fragment made by PCR that encoded the 188 nt chimeric ribozyme was ligated into plasmid pRzA that had been double-digested with XbaI and KpnI (Figure 3) . The in vivo tissue culture plasmid pRNA-CRzA encoding the chimera ribozyme was constructed by using XbaI and KpnI to remove the sequence encoding the unmodified ribozyme from the plasmid pCRzA that encoded the ribozyme targeting the HBV polyA signal. 41 Then, a dsDNA fragment made by PCR that encoded the 188 nt chimeric ribozyme was ligated into the position of the plasmid pCRzA that had been double-digested with XbaI and KpnI (Figure 3 ).
Elongation of pRNA at the 3 0 end and testing the activities of mutant pRNA with 3 0 -end extensions
The RNA products Eco-pRNA and XbHi-pRNA were produced by in vitro T 7 RNA polymerase transcription using DNA templates from plasmid pCRTM2 that were precleaved with EcoR1 or XbaI/HindIII, respectively. To generate the plasmid pCRTM2, a PCR DNA fragment was produced with the primer pair P7/P11 to flank the pRNA coding sequence. 38 The PCR fragment Figure 6 Secondary structure 27 (a) and 3D computer model 22 (b) of pRNA dimer. Lines between residues of the monomer subunits of the dimer in (a) show that the bases of the left-and right-hand loops interact intermolecularly via hand-in-hand interaction. 43, 44 Figure 7 Potential uses of the phi29 pRNA as polyvalent vector system for delivery and therapy. pRNA multimers could be used to target a cell receptor and to codeliver therapeutic ribozymes or other biologically active molecules.
phi29 pRNA as ribozyme escort to destroy hepatitis B virus S Hoeprich et al was then cloned into the PCR cloning vector pCRtII (Invitrogen). DNA sequencing after colony isolation confirmed the presence of the PCR fragment in the plasmid. The RNA product 174-pRNA was either extracted from procapsids 21, 54 or transcribed in vitro with a PCR DNA fragment generated using the plasmid pCl3-12A(RNA) as template, following the method described in Wichitwechkarn et al.
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The RNA product Di-RNA with a 120-base extension from the 3 0 -end of pRNA was transcribed in vitro with a PCR DNA fragment using cpDNAT7 38, 55 as template for a PCR reaction.
In vitro synthesis of RNA RNAs were prepared as described previously. 29 Briefly, DNA oligos were synthesized with the desired sequences and used to produce double-stranded DNA by PCR. The DNA products containing the T 7 promoter were cloned into plasmids or used as substrate for direct in vitro transcription. The in vitro plasmid pTZS encoding the HBV polyA 41 substrate was linearized with BglII. The in vitro plasmids encoding the HBV polyA substrate targeting ribozyme RzA and the pRNA chimera ribozyme pRNA-RzA were linearized with EcoRI. RNA was produced by in vitro transcription with T 7 polymerase using a linear DNA as a template for run-off transcripts. The antisense DNA encoding the U7 substrate and the DNA encoding ribozyme RzU7 were mixed with the T 7 sense promoter prior to transcription. The dsDNA encoding ribozyme RzU7-pRNA and T 7 promoter were made by PCR. RNA was synthesized with T 7 RNA polymerase by run-off transcription and purified from polyacrylamide gels. The sequences of both plasmids and PCR products were confirmed by DNA sequencing.
The transcribed RNA sequences are as follows. Ribozyme pRNA-RzA (HBV study):
Ribozyme RzA (HBV study):
0 GCUAGUUCUAGACAAAUUCUUUAGUCCGU GAGGACGAAACGGGUCGGUACCUCGACGUC3 0 U7 fragment in vitro substrate (U7 study):
0 GGGAAAGCUUAUAGUGUUACAGCUCUUUUA GAAUUUGUCUAGCAGGUUUUCUGACUUCGGUCG GAAAACGCCUAACGUUGCAUGCCUGCAGGUC3 0 Ribozyme RzU7 (U7 study):
0 GGCAAAUUCUAAAACUGAUGAGUGACGAA AGCUGUAACAC3 0 Ribozyme pRNA-RzU7 (U7 study):
In vitro cleavage by hammerhead ribozyme
The HBV polyA targeting ribozyme RzA and ribozyme pRNA-RzA cleavage reactions were performed at 371C for 60 min in the presence of 20 mM Tris pH 7.5 and 20 mM MgCl 2 . Ribozyme pRNA-RzA (0.539 nmol) was used to cleave HBV-polyA (0.117 nmol). The U7-targeting ribozyme RzU7 and the ribozyme RzU7-pRNA cleavage reactions were performed at 371C for 90 min in the presence of 20 mM Tris pH 7.5, 20 mM MgCl 2 , and 150 mM NaCl. In both in vitro studies, control reactions were performed by substituting water for RNAs. The samples were dialyzed against TE (10 mM Tris, 1 mM EDTA, pH 8.0) for 30 min on a Millipore 0.025 mm VS type membrane prior to loading them on a 15% PAGE/ 8 M urea-denaturing gel.
Cell culture and transient transfection
The HepG2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and antibiotics at 371C and 10% CO 2 . Transient transfection was carried out with the method of calcium phosphate precipitation. In general, cells in 60-mm dishes were transient transfected with 1 mg of Figure 8 Phylogenetic analysis reveals similar secondary structures of various viral DNA-packaging pRNAs. All these pRNAs are potential vectors for carrying therapeutic RNA molecules.
phi29 pRNA as ribozyme escort to destroy hepatitis B virus S Hoeprich et al HBV expression plasmid p3.6II 41 and 5 mg of expression construct (CMV vector, pCRzA plasmid 41 or pRNA-RzA plasmid). A volume of 1 mg of pcDNA4LacZ carrying lacZ gene (Invitrogen) was also included in each transfection as internal control. b-galactosidase activity was detected to normalize the transfection efficiency among different dishes.
Analysis of HBV viral RNA transcription
At 72 h after transfection, the cells were harvested and lysed in Trizol reagents (Gibcol-BRL) for total RNA extraction. For Northern blot, 20 mg of denatured RNA was resolved in a 0.6 M formaldehyde-1% agarose gel and transferred onto Hybond N+ nylon membrane (Amersham). Probes were prepared by random priming with the 1.8 kb XbaI fragment of HBV (adr) from plasmid p3.6 II and [a- 32 P] dATP according to the supplier (Promega). After hybridization with HBV probe, the blot was stripped and rehybridized with a probe of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that served as an internal control for normalizing the level of total cell RNA.
Analysis of e-Ag
At 72 h after transfection, cells were harvested and lysed in a buffer (1% NP-40, 50 mM Tris-HCl, and 1 mM EDTA) at 371C for 10 min. Activity of b-galactosidase in cell lysate was determined to normalize the variation of transfection efficiency among different samples. e-Ag in cell lysates and media were assayed with a commercial ELISA kit (Sino-American Co.) (Table 3) .
